Skip to main content

Table 5 Albumin and glucose

From: A randomized controlled pilot study to evaluate the effect of an enteral formulation designed to improve gastrointestinal tolerance in the critically ill patient—the SPIRIT trial

  Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
  n Median (IQR) n Median (IQR) Median differencea (95% CI)  
Serum albumin at baseline 39 21.0 (17.0–25.0) 42 21.3 (18.0–24.0) 0.0 (−2.0 to 2.0) 0.93
Serum albumin at treatment end or at ICU discharge 17 21.0 (19.0–26.0) 19 23.0 (18.0–26.0) 0.00 (−3.00 to 3.00) 0.99
  n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)
Number of events outside the 4.5–10 mmol/l glycemic range 46 425 (253 pd) 44 582 (287 pd) 0.83 (0.54–1.28) 0.39
  1. aHodges–Lehmann median differences
  2. CI confidence interval, ICU intensive care unit, IQR interquartile range, pd person days